AU2015218775C1 - Antimitotic amides for the treatment of cancer and proliferative disorders - Google Patents

Antimitotic amides for the treatment of cancer and proliferative disorders Download PDF

Info

Publication number
AU2015218775C1
AU2015218775C1 AU2015218775A AU2015218775A AU2015218775C1 AU 2015218775 C1 AU2015218775 C1 AU 2015218775C1 AU 2015218775 A AU2015218775 A AU 2015218775A AU 2015218775 A AU2015218775 A AU 2015218775A AU 2015218775 C1 AU2015218775 C1 AU 2015218775C1
Authority
AU
Australia
Prior art keywords
unsubstituted
substituted
alkyl
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015218775A
Other languages
English (en)
Other versions
AU2015218775B2 (en
AU2015218775A1 (en
Inventor
Adam Siddiqui-Jain
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Frost Biologic Inc
Original Assignee
Frost Biologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frost Biologic Inc filed Critical Frost Biologic Inc
Publication of AU2015218775A1 publication Critical patent/AU2015218775A1/en
Publication of AU2015218775B2 publication Critical patent/AU2015218775B2/en
Application granted granted Critical
Publication of AU2015218775C1 publication Critical patent/AU2015218775C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2015218775A 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders Active AU2015218775C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461942956P 2014-02-21 2014-02-21
US61/942,956 2014-02-21
PCT/US2015/016928 WO2015127284A2 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Publications (3)

Publication Number Publication Date
AU2015218775A1 AU2015218775A1 (en) 2016-08-25
AU2015218775B2 AU2015218775B2 (en) 2019-06-20
AU2015218775C1 true AU2015218775C1 (en) 2020-01-16

Family

ID=52684675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015218775A Active AU2015218775C1 (en) 2014-02-21 2015-02-20 Antimitotic amides for the treatment of cancer and proliferative disorders

Country Status (15)

Country Link
US (5) US10016398B2 (cg-RX-API-DMAC7.html)
EP (1) EP3107909B1 (cg-RX-API-DMAC7.html)
JP (1) JP6506313B2 (cg-RX-API-DMAC7.html)
KR (1) KR102420508B1 (cg-RX-API-DMAC7.html)
CN (2) CN114634483B (cg-RX-API-DMAC7.html)
AU (1) AU2015218775C1 (cg-RX-API-DMAC7.html)
BR (1) BR112016019161B1 (cg-RX-API-DMAC7.html)
CA (1) CA2940237C (cg-RX-API-DMAC7.html)
ES (1) ES2893374T3 (cg-RX-API-DMAC7.html)
IL (1) IL247293B (cg-RX-API-DMAC7.html)
MX (1) MX390530B (cg-RX-API-DMAC7.html)
RU (1) RU2713179C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202000590SA (cg-RX-API-DMAC7.html)
WO (1) WO2015127284A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201606471B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420622B1 (en) 1997-08-01 2002-07-16 3M Innovative Properties Company Medical article having fluid control film
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas
CN106727583A (zh) * 2016-12-12 2017-05-31 范旭升 一种治疗舒张性心衰的药物组合物
US11377436B2 (en) * 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
US11760701B2 (en) 2018-02-27 2023-09-19 The Research Foundation For The State University Of New Yrok Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
WO2025248483A1 (ko) * 2024-05-30 2025-12-04 삼진제약주식회사 Nr2f6 억제제 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263612A1 (en) * 2010-04-27 2011-10-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012107475A1 (en) * 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012151355A1 (en) * 2011-05-03 2012-11-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2013063385A1 (en) * 2011-10-28 2013-05-02 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
NZ522990A (en) * 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds
JP2008505145A (ja) * 2004-06-30 2008-02-21 ノバルティス アクチエンゲゼルシャフト 排出ポンプ阻害剤を用いてペプチドデホルミラーゼ阻害剤の感受性を増加するための方法
EP1921066A4 (en) * 2005-08-11 2010-07-07 Takeda Pharmaceutical Pyridylphenol compound and its use
AU2007211276B2 (en) * 2006-01-31 2013-06-06 Synta Pharmaceuticals Corp. Pyridylphenyl compounds for inflammation and immune-related uses
ATE524465T1 (de) 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
US20100130496A1 (en) * 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2010039236A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
NZ598758A (en) * 2009-09-11 2013-12-20 Amgen Inc N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
WO2011142151A1 (ja) * 2010-05-14 2011-11-17 シャープ株式会社 携帯型情報端末およびその制御方法
TWI541243B (zh) * 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
JP2014503000A (ja) * 2011-01-21 2014-02-06 アッヴィ・インコーポレイテッド キナーゼのピコリンアミド阻害剤
BR112016019161B1 (pt) * 2014-02-21 2022-12-20 Frost Biologic, Inc Amidas antimitóticas, composições farmacêuticas que as compreendem e uso das mesmas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110263612A1 (en) * 2010-04-27 2011-10-27 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2012107475A1 (en) * 2011-02-10 2012-08-16 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2012151355A1 (en) * 2011-05-03 2012-11-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2013063385A1 (en) * 2011-10-28 2013-05-02 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2011-08-14), Database accession no. 1317573-81-1 *
REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (2015-02-10), Database accession no. 1646329-57-8 *

Also Published As

Publication number Publication date
US10772872B2 (en) 2020-09-15
CA2940237C (en) 2023-03-07
IL247293A0 (en) 2016-09-29
JP6506313B2 (ja) 2019-04-24
JP2017506267A (ja) 2017-03-02
US20260034101A1 (en) 2026-02-05
US12383533B2 (en) 2025-08-12
KR102420508B1 (ko) 2022-07-13
MX390530B (es) 2025-03-20
RU2016135555A3 (cg-RX-API-DMAC7.html) 2018-10-05
WO2015127284A2 (en) 2015-08-27
CN114634483B (zh) 2024-08-13
SG11201606869TA (en) 2016-09-29
IL247293B (en) 2021-01-31
KR20160116009A (ko) 2016-10-06
ES2893374T3 (es) 2022-02-08
US10016398B2 (en) 2018-07-10
US20220008395A1 (en) 2022-01-13
CN114634483A (zh) 2022-06-17
MX2016010877A (es) 2017-05-04
SG10202000590SA (en) 2020-03-30
ZA201606471B (en) 2025-06-25
EP3107909B1 (en) 2021-07-14
WO2015127284A3 (en) 2015-10-15
BR112016019161B1 (pt) 2022-12-20
RU2713179C2 (ru) 2020-02-04
US20170172984A1 (en) 2017-06-22
AU2015218775B2 (en) 2019-06-20
RU2016135555A (ru) 2018-03-28
US11129813B2 (en) 2021-09-28
EP3107909A2 (en) 2016-12-28
BR112016019161A2 (cg-RX-API-DMAC7.html) 2017-08-15
CN106068263A (zh) 2016-11-02
CA2940237A1 (en) 2015-08-27
AU2015218775A1 (en) 2016-08-25
US20180325871A1 (en) 2018-11-15
US20200397758A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
US12383533B2 (en) Antimitotic amides for the treatment of cancer and proliferative disorders
CA3095019C (en) Substituted pyridine derivatives and compositions thereof useful as inhibitors of histone demethylases
US8163777B2 (en) Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
JP2010504913A (ja) 炎症及び免疫関連使用のための縮合環化合物
US20090203667A1 (en) Pentadienamide derivatives
TW200307535A (en) Therapeutic agent for cancer
JP5094721B2 (ja) N−フェニル−2−ピリミジン−アミン誘導体及びそれの調製のための工程
CA3095164A1 (en) Calpain modulators and therapeutic uses thereof
EA036542B1 (ru) Галоген-замещенные пиперидины в качестве модуляторов орексинового рецептора
US20130289071A1 (en) Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
JP6569678B2 (ja) 2−アミノチアゾール誘導体またはその塩
CA2950250A1 (en) 1h-1,8- naphthyridin-2ones as anti proliferative compounds
KR101297652B1 (ko) 항암활성을 지닌 카르보아졸계 화합물
CN118434743A (zh) 三环杂环类
HK1232858B (en) Antimitotic amides for the treatment of cancer and proliferative disorders
MX2014001052A (es) Compuesto novedoso que tiene actividad inhibidora de angiogénesis, metodo para preparar del mismo, y composicion farmaceutica que comprende el mismo.
WO2012115066A1 (ja) グリシントランスポーター阻害物質

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 SEP 2019

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 05 SEP 2019

FGA Letters patent sealed or granted (standard patent)